Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study

Systemic anti-cancer therapy (SACT) is widely used in the treatment of lung cancer for both curative-intent settings where treatment is given to reduce the risk of recurrence, and in palliative-intent settings where treatment is given to prolong survival and mitigate symptoms [1,2]. While SACT is a powerful tool for managing lung cancer, it is not without serious side-effects. In order for SACT to be effective, patients must be able to withstand not only the immediate side-effects but to survive long enough for the benefits of SACT to be realized.

Source: Lung Cancer - June 5, 2019 Category: Cancer & Oncology Authors: Amanda J.W. Gibson, Haocheng Li, Adrijana D ’Silva, Anifat A. Elegbede, Roxana A. Tudor, Shannon Otsuka, D. Gwyn Bebb, Winson Y. Cheung Source Type: research